Concepedia

Shakti Valdez

SV

6

Publications

151

Citations

6

H-Index

2010

Active since

Affiliations

AstraZeneca (United States)(Current)

The University of Texas Southwestern Medical Center

Anaheim Clinical Trials

Metroplex Clinical Research Center

Shakti Valdez is an author at AstraZeneca (United States) specializing in medicine, vascular biology, and extracellular matrix.

Top concepts

Publications per year

2010–2018

6

Publications

6

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study

R. Fleischmann, Peter Winkle, Jeffrey N. Miner et al. · RMD Open · 2018 · 39 citations · Full text

Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat

Angela Chen, Frank A. DeLano, Shakti Valdez et al. · American Journal of Physiology-Cell Physiology · 2010 · 33 citations · Full text

, , +23

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers

Michael Gillen, Shakti Valdez, Dongmei Zhou et al. · Drug Design Development and Therapy · 2016 · 31 citations · Full text

Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide

Michael Gillen, Chun Yang, David M. Wilson et al. · Clinical Pharmacology in Drug Development · 2017 · 25 citations

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study

Roy Fleischmann, Peter Winkle, Jesse Hall et al. · RMD Open · 2018 · 13 citations · Full text

Rows per page

1–5 of 6